NCT05052229View on ClinicalTrials.gov

Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF).

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 21, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

February 28, 2025

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Nitric Oxide

Nitric oxide gas for inhalation

DRUG

Medical air

Medical grade air for inhalation (placebo)

Trial Locations (1)

K7L 2V7

RECRUITING

Respiratory Investigation Unit, Kingston General Hospital, Kingston

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Dr. Denis O'Donnell

OTHER